Ali Shakerimoghaddam

Dr. Ali Shakerimoghaddam


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in GERMS
Verified
Journal Article
Open access
MGMitra Garousi
Mitra Garousi
STSina Monazami Tabar
Sina Monazami Tabar
HMHosein Mirazi
Hosein Mirazi
ZFZahra Farrokhi
Zahra Farrokhi
AKAzad Khaledi
Azad Khaledi
ASAli Shakerimoghaddam
Ali Shakerimoghaddam
Pseudomonas aeruginosa is one of the most common causes of diabetic foot infection globally. This study aimed to determine the global distribution of P. aeruginosa isolated from diabetic foot ulcer infection.


22 October 2024 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
SNSeyed Pooria Tadayon Nabavi
Seyed Pooria Tadayon Nabavi
MCMohsen Chamanara
Mohsen Chamanara
AMArasb Dabbagh Moghaddam
Arasb Dabbagh Moghaddam
MGMahdi Ghorbani
Mahdi Ghorbani
RHReza Heidari
Reza Heidari
ASAli Shakerimoghaddam
Ali Shakerimoghaddam
One of the main risks of infection after hematopoietic stem cell transplantation (HSCT) is infection by gram-positive bacteria, including vancomycin-resistant enterococci (VRE). Based on the format of a global review and meta-analysis study, this study aims to investigate the incidence of VRE bloodstream infection (BSI) after HSCT in colonized individuals. The keywords of the systematic search included vancomycin-resistant enterococci and HSCT. These words were searched in Google Scholar, PubMed/Medline, Scopus, and Web of Science databases from January 1, 2000, to March 1, 2024. Studies that reported the prevalence of vancomycin-resistant enterococci in patients undergoing HSCT were included. The random effects model was used for the meta-analyses. Investigations were conducted according to PRISMA guidelines, and the protocol was registered in PROSPERO: CRD42024543491. Out of 1100 screened papers, 28 were eligible. The random effects model was established to analyze the incidence of VRE BSI after HSCT. The pooled prevalence of co-infection for Allo-HSCT recipients was 3.023 (95% CI, Z-value = -3.5, p-value < 0.0001), and this value for Auto-HSCT recipients was 11.89 (95% CI, Z-value = -2.923, p-value < 0.001). These results showed that the rate of BSI due to vancomycin-resistant enterococcus in Auto-HSCT recipients is higher than Allo-HSCT. The prevalence of vancomycin-resistant enterococci in Auto-HSCT recipients is higher than that of Allo-HSCT, possibly due to colonization of the intestines of these people with vancomycin-resistant enterococci before transplantation. VRE Colonization before transplantation increases the likelihood of post-transplant VRE BSI and other bacterial infections, including Gram-negative. The strains should be analyzed by sequencing before and after HSCT for a more detailed investigation.

5 April 2025 in Nano LIFE
Verified
Journal Article
Closed access
MNMohammad Najafi
Mohammad Najafi
MOMohammad Hassan Omidi
Mohammad Hassan Omidi
SHSakineh Hajebi
Sakineh Hajebi
ZKZahra Khoddam
Zahra Khoddam
MCMohsen Chamanara
Mohsen Chamanara
Reza HeidariReza Heidari
Reza Heidari

12 October 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AKAmirvala Keyhani
Amirvala Keyhani
AGAli Gholami
Ali Gholami
MCMohsen Chamanara
Mohsen Chamanara
MGMahdi Ghorbani
Mahdi Ghorbani
RHReza Heidari
Reza Heidari
ASAli Shakerimoghaddam
Ali Shakerimoghaddam
Background: MPOX-VZV co-infection poses diagnostic challenges and public health implications due to the overlap in clinical presentation and complications. Evidence on the epidemiology and clinical outcomes of MPOX-VZV co-infection remains limited. This systematic review and meta-analysis summarize the available epidemiological evidence and discusses the associated diagnostic and public health implications. Methods: A systematic and comprehensive literature search was performed in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and the Cochrane Library for studies published between January 2000 and October 2024, following PRISMA guidelines. We included studies that reported MPOX–VZV coinfection prevalence. Standard methods were used for data extraction and meta-analysis, and methodological quality was assessed using the Appraisal tool for Cross-Sectional Studies (AXIS). The pooled prevalence was derived from a random-effects meta-analysis; heterogeneity was evaluated with Cochran’s Q and I² statistics. Sensitivity analysis and tests for small-study effects were also performed (Egger’s regression, Begg’s test, and funnel plots). Subgroup analyses by region of residence and study period were also performed using the random-effects model. Results: Of the 860 records identified, 12 studies were eligible for inclusion, with data from the Democratic Republic of Congo, Nigeria, Brazil, Central African Republic, and Pakistan. The pooled prevalence across the included study populations was 21.3% (95% CI: 15.0–29.4%, Z = 5.93, P < 0.001). There was substantial heterogeneity (I²=93.6%), and event rates varied by region, study design, and diagnostic approach. The sensitivity analyses showed event rates ranging from 17.8% to 27.2% (I²=93.6%). Egger’s and Begg’s tests were non-significant; however, with only 12 studies, publication bias could not be excluded. Subgroup analyses showed comparable pooled prevalence between endemic and non-endemic settings and between the pre-2022 and 2022-outbreak periods, with neither region of residence nor study period reaching statistical significance as a moderator of prevalence (Q-between p = 0.907 and p = 0.132, respectively). Conclusions: In the included study populations, MPOX–VZV coinfection was observed in approximately one in five patients with mpox, but this estimate should be interpreted cautiously because of substantial heterogeneity and limited geographic coverage. Improved differential diagnostics, integrated surveillance, clinician awareness, and targeted public health interventions are recommended, particularly in endemic settings. Future research should clarify the epidemiology and clinical significance of coinfection and distinguish primary varicella from VZV reactivation.